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INTRODUCTION

Interleukin-17 (IL-17)-producing helper T cells (Th17 cells) have been identified as a distinct subset of effector CD4
+ T cells and are considered critical drivers of autoimmune tissue inflammation (Bettelli and Kuchroo, 2005; Korn et al., 2009 ). Differentiation of naive CD4 + T cells into Th17 cells is achieved with the cytokines transforming growth factor (TGF)-b1 and IL-6 (Bettelli et al., 2006) . This cytokine combination, however, generates Th17 cells, which co-produce IL-10 together with IL-17 and do not induce autoimmunity (Lee et al., 2012; McGeachy et al., 2007) and have therefore been called non-pathogenic Th17 cells. To acquire the ability to induce autoimmunity in vivo, IL-17-producing T cells need to either be re-stimulated with IL-23 (McGeachy et al., 2009) or be generated with alternative cytokine combinations triggering IL-23 receptor (IL-23R) expression and signaling, such as IL-1b, IL-6, and IL-23 (Ghoreschi et al., 2010) or TGF-b3 and IL-6 (Lee et al., 2012) . IL-23R controls the production of a proinflammatory transcriptional module in Th17 cells (Lee et al., 2012) , including many essential effector cytokines (Codarri et al., 2011; El-Behi et al., 2011) . IL-23R is thus a key determinant of the pathogenicity of Th17 cells and of autoimmunity in general (Cua et al., 2003) . Understanding the mechanism by which IL-23R regulates the functional phenotype of pathogenic and non-pathogenic Th17 cells and how this balance is transcriptionally regulated is therefore critical for the selective inhibition of pathogenic Th17 cells in human autoimmune diseases.
Differentiation of Th17 cells is transcriptionally controlled by the lineage-defining transcription factor RORgt (Ivanov et al., 2006; Xiao et al., 2014) , and the transcriptional networks controlling Th17 cell differentiation have recently been identified in large-scale transcriptomic analyses (Ciofani et al., 2012; Yosef et al., 2013) . Our study predicted that Notch signaling and RBPJ, a downstream regulator of Notch signaling, were two of the 22 major nodes that positively regulated the development of Th17 cells (Yosef et al., 2013) . This is consistent with previous studies that demonstrated that pharmacological and antibodymediated inhibition of Notch ameliorated Th17-dependent autoimmune disease models (Bassil et al., 2011; Jurynczyk et al., 2008; Keerthivasan et al., 2011; Reynolds et al., 2011) . Despite these detailed transcriptomic data, the molecular mechanism by which Notch regulates Th17 development has not been identified. In addition, which subtype of Th17 cells (pathogenic or non-pathogenic) is regulated by Notch signaling has not been addressed.
Here we demonstrate that the canonical Notch signaling molecule RBPJ in Th17 cells regulates the development of pathogenic and non-pathogenic Th17 cells. We show that RBPJ directly promotes the expression of IL-23R by binding and trans-activating the Il23r promoter and repressing anti-inflammatory IL-10 production in Th17 cells. Consistent with this observation is that RBPJ-deficient Th17 cells show a non-pathogenic Th17 transcriptional profile, that RBPJ deficiency in Th17 cells protects mice from the development of experimental autoimmune encephalomyelitis (EAE), and that IL-23R overexpression rescues this defect. We have therefore identified a transcription factor that controls the generation of pathogenic and non-pathogenic Th17 cells by directly driving IL-23R expression and repressing production of the anti-inflammatory cytokine IL-10.
RESULTS
RBPJ Is Required for the Pathogenicity of Th17 Cells
IL-23R is essential for the pathogenicity of Th17 cells, but its transcriptional control is unknown. We previously identified Notch1 and RBPJ, which form the Notch signaling pathway, as predicted positive regulators of Th17 cell differentiation (Yosef et al., 2013) . However, the exact role of Notch signaling in Th17 cells was not analyzed. In a time course expression analysis, RBPJ had high expression and was continuously upregulated in Th17 cells (Figures S1A-S1C). We therefore generated CD4
Cre RBPJ fl/fl mice and found that RBPJ deficiency in T cells did not affect Th17 differentiation in the presence of TGF-b1 and IL-6, a condition that induces non-pathogenic Th17 cells independent from IL-23 (Lee et al., 2012 ; Figure 1A ). Under these non-pathogenic conditions, CD4 Cre RBPJ fl/fl Th17 cells instead showed a dramatic increase in IL-10 production (Figures 1A and 1B) . When differentiated with IL-1b + IL-6 + IL-23, which generates pathogenic Th17 cells dependent on IL-23 (Ghoreschi et al., 2011) , naive CD4 Cre RBPJ fl/fl cells showed a significant decrease in IL-17 expression ( Figures 1C and 1D ). In addition, such pathogenic Th17 cells from CD4
Cre RBPJ fl/fl mice began to produce IL-10 ( Figure 1D ), which is normally not observed under these conditions. Also, memory T cells from CD4
Cre RBPJ fl/fl mice that were stimulated with IL-23 showed an increase in IL-10 ( Figure 1E ), although IL-23 suppresses IL-10 production from wild-type Th17 cells (Lee et al., 2012; McGeachy et al., 2009 
CD4
Cre RBPJ fl/fl mice developed reduced peak severity and had faster recovery from EAE, but disease onset was unchanged (Figures 1F and 1G) , consistent with RBPJ deficiency affecting the generation of pathogenic Th17 cells. We isolated CNS-infiltrating mononuclear cells from mice with EAE ( Figure S1D ) and found a decrease in IL-17A-producing and IL-17A/interferon g (IFN-g) double-producing CD4 + T cells in the CNSs of
Cre RBPJ fl/fl mice at the peak of EAE ( Figure 1H ), and IL-17A + IFN-g + T cells are generally considered to be pathogenic in EAE (Abromson-Leeman et al., 2009) . There was no effect on IFN-g-producing single-positive T cells and on the production of other cytokines in the CNS at early time points ( Figure S1D ). At the time of recovery, production of anti-inflammatory IL-10 by CD4 + T cells in the CNS in CD4 Cre RBPJ fl/fl mice was increased ( Figures 1I and 1J ), whereas IL-23-dependent early generation of Th17 cells in draining lymph nodes in CD4
Cre RBPJ fl/fl mice was reduced ( Figure S1E ). We thus hypothesized that RBPJ promotes the pathogenicity of Th17 cells by altering their ability to respond to pro-inflammatory IL-23 and/or by repressing the production of anti-inflammatory IL-10. RBPJ is known to have a role in the differentiation of other T helper cells (Amsen et al., 2009) , and, accordingly, we observed an increased differentiation of Th1 cells ( Figure S1F ) and decreased generation of induced regulatory T cells (iTregs) ( Figure S1G ) in CD4
Cre RBPJ fl/fl mice. To circumvent these nonTh17-derived effects, we crossed RBPJ fl/fl mice to IL17A
Cre mice to delete RBPJ only in IL-17A-producing cells. The differentiation of Th1 ( Figure S2A ) and iTreg ( Figure S2B) Figure 2H ). Production of other cytokines was unchanged ( Figure S2D ). Moreover, the IL-23-dependent generation of Th17 cells was affected in the periphery ( Figure S2E ), and IL17A
Cre RBPJ fl/fl cells produced more IL-10 at recovery ( Figure 2I Figure 2J ), although their IL-17 production before transfer was unchanged ( Figure S2G ). Our data obtained with this targeted deletion of RBPJ thus indicate that RBPJ is required specifically for the differentiation of pathogenic Th17 cells generated with IL-23 and that loss of RBPJ results in an increase in anti-inflammatory IL-10 and loss of pathogenicity in vivo. RBPJ deficiency thus causes the generation of non-pathogenic Th17 cells even under pathogenic Th17 differentiation conditions. Notch signaling controls various aspects of CD4 + T cell function, including chemokine receptor expression (Reynolds et al., 2011) and viability of memory T cells (Helbig et al., 2012; Maekawa et al., 2015) . We did not find evidence for an altered expression of Ccr6 ( Figure S3A ) or an altered survival of RBPJdeficient Th17 cells in vitro ( Figure S3C ) or in vivo ( Figures S3D  and S3E ), arguing for a specific effect of RBPJ on the pathogenicity of Th17 cells under IL-23-dependent Th17 differentiation conditions. We next investigated the mechanism of how RBPJ enhanced pathogenicity of Th17 cells.
RBPJ Controls the Expression of IL-23R in Th17 Cells
We performed a multiplex gene expression analysis using nanostring technology, applying a codeset of 200 predefined Th17-related transcripts (Yosef et al., 2013) and comparing the results with a previously defined pathogenic/non-pathogenic Th17 gene signature (Lee et al., 2012 Figure 3B ). These transcripts were previously identified as part of a pro-inflammatory module in pathogenic Th17 cells (Lee et al., 2012) . In addition, Il17a, which is the effector cytokine of pathogenic Th17 cells, was downregulated under both conditions in IL17A (I) The cytokine production by CNS-infiltrating CD4 + cells was assessed on d28, and the proportion of IL-10-producing CD4 + T cells was calculated.
(J) CNS-infiltrating CD4 + T cells were sorted from RBPJ flox/flox (n = 3) and CD4 Cre RBPJ flox/flox (n = 3) mice, and relative Il10 expression was measured by qPCR using GAPDH as a housekeeping gene. Results are summed from three independent experiments in (F-I), with three individual mice analyzed per group in (H) and (I). *p < 0.05, **p < 0.01. See also Figure S1 .
IL-23 promotes the pathogenicity and stability of Th17 cells. We next addressed whether RBPJ affects the stability of the Th17 cell lineage by crossing IL17A
Cre RBPJ fl/fl mice with R26 RFP mice, generating IL-17A fate reporter mice as described previously (Hirota et al., 2011; Figure S3F high CD44 low CD25 À T cells were sorted from wild-type 2D2 and CD4 Cre RBPJ fl/fl 2D2 mice and differentiated in vitro with TGF-b1, IL-6, and IL-23. Sfter 7 days of culture, 5 3 10 6 cytokine-producing T cells were intravenously injected into C57BL/6 wild-type recipients.
The data in (G-I) are summed from three independent experiments with 3-5 mice/group. *p < 0.05, **p < 0.01. See also Figure S2 . ) mice were immunized with MOG , and, at the peak of EAE, draining lymph nodes cells were cultured in the presence of 1 mg/ml MOG and IL-23 for 5 days. Intracellular cytokine production was assessed after gating on CD4 + (top) and CD4 Cross-linked protein-DNA complexes were immunoprecipitated using an anti-RBPJ antibody. DNA was purified and used for qPCR with primers spanning parts of the Il23r promoter predicted to contain RBPJ binding sites, indicated as horizontal bars in the schematic of the Il23r locus. in, intron; p, promoter. DNA binding was calculated as percentage of input DNA. One representative of three independent experiments with three replicate samples per immunoprecipitation (IP) is shown.
(B) Il23r promoter activity was measured in HEK293T cells transfected with a luciferase vector driven by 2.7 kb of the IL23R promoter (pGL4-IL23R) and increasing amounts of constructs encoding c-Maf and (ca)RBPJ (RBPJ-VP16).
(C) IL23r promoter activity was measured after transfection with a luciferase vector driven by 1.5 kb of the IL23R promoter (pTA-IL23R) and constructs encoding c-Maf and caRBPJ (RBPJ-VP16). Luciferase activity induced by c-Maf and RBPJ-VP16 was measured using a pTA-IL23R promoter construct with mutated RBPJ binding site p2 (pTA-IL23R
Dp2
). (D) pGL4-IL23R luciferase activity was measured after transfection with combinations of RBPJ, caRBPJ, and c-Maf constructs.
conditions. We also tested how efficiently the RBPJ fl/fl allele was deleted by the IL17A
Cre allele and found a marked reduction but no absence of RBPJ in CD4 + RFP + cells ( Figure S3H Figure 3G ). IL-23R surface levels were also reduced in pathogenic Th17 cells from CD4 Cre RBPJ fl/fl mice stained with an anti-IL-23R antibody (Figure 3H) , confirming that RBPJ is, in fact, required to induce IL-23R protein expression in Th17 cells. A reduction in IL-23R expression was also observed in RBPJ-deficient non-pathogenic Th17 cells, albeit at lower levels because of the low expression of IL-23R under these conditions (data not shown). Furthermore, activation of the Notch pathway by overexpression of the intracellular domain of Notch receptors 1-3 (NICD) also induced surface expression of IL-23R in Th17 cells ( Figure S4A ). RBPJ and the Notch signaling pathway thus promote expression of the IL-23R, and RBPJ is consequently required for the stability and pathogenicity of Th17 cells.
RBPJ Binds and trans-Activates the Il23r Promoter in Cooperation with RORgt
We next addressed how RBPJ controls the expression of the IL-23R on a transcriptional level. We identified canonical RBPJ binding sites (Wang et al., 2011) in the proximal and distal promoter region ( Figure 4A ) and in both enhancer regions in intron 3 and intron 6 of the Il23r gene ( Figure 4A ), where Th17-related transcription factors such as RORgt bind (Xiao et al., 2014) . To experimentally test for binding of RBPJ, we performed chromatin immunoprecipitation (ChIP) PCR of the predicted RBPJ binding sites. Il23r promoter regions-preferentially a region $1,100 bp upstream of the transcriptional start site termed p2-showed enriched binding ( Figure 4A ), indicating that RBPJ indeed binds the Il23r promoter. Of note, the site with most enrichment (p2) is distinct from sites bound by other Th17 cell-related transcription factors (Ciofani et al., 2012; Xiao et al., 2014; Yosef et al., 2013) .
Using a previously described IL23R promoter luciferase construct spanning 1.2 kb of the Il23r promoter (pTA-Il23r), constitutively active (ca) RBPJ (RBPJ-VP16) trans-activated the Il23r promoter ( Figure 4B ). c-Maf, which is known to activate Il23r expression (Sato et al., 2011) , was used as a positive control. Mutating site p2 in this construct abrogated its activation by caRBPJ but not by c-Maf ( Figure 4C ). This indicates that RBPJ directly controls transcription from the Il23r promoter dominantly through the p2 binding site, which is distinct and independent from other Th17 cell-related transcription factors. We next tested whether non-modified RBPJ exerted repressive effects on the Il23r promoter. Non-modified RBPJ had no effect on c-Maf-induced Il23r promoter activation, whereas caRBPJ had additive effects together with c-Maf on the Il23r luciferase construct ( Figure 4D) . Thus, the Notch pathway drives IL-23R expression through direct transcriptional control.
We next addressed whether RBPJ acted independently or in cooperation with the Th17 cell lineage-defining transcription factor RORgt, which was previously shown to bind the Il23r promoter at moderate levels (Ciofani et al., 2012; Xiao et al., 2014) . Retroviral overexpression of caRBPJ induced IL23R GFP reporter expression even in Th0 cells, which do not express RORgt ( Figure 4E ). Also, caRBPJ induced surface expression of IL-23R in the absence of RORgt in CD4 Cre RORgt flox/flox cells cultured in the presence of IL-1b + IL-6 + IL-23 ( Figure 4F ). In accordance, both caRBPJ and RORgt individually activated the Il23r promoter luciferase construct and, when combined, exhibited an additive effect in inducing IL-23R expression (Figure 4G) . RBPJ did not interact directly with RORgt on the protein level ( Figure S4B ). Taken together, our data indicate that the Th17 transcriptional program is not required for RBPJ to promote the expression of IL-23R but that RBPJ and RORgt may work in a combinatorial manner to induce maximum expression of IL-23R but do not form a protein-protein complex.
The Dominant Function of RBPJ in Th17 Cells Is to Maintain IL-23R Expression
Our data indicate that RBPJ controls the generation and stability of pathogenic Th17 cells by directly driving IL-23R transcription. Previous studies, however, had reported that Notch controls transcription of IL-17A and RORgt itself, although not testing for changes in IL-23R expression (Keerthivasan et al., 2011; Mukherjee et al., 2009) , and we replicated these findings ( Figures  S5A-S5C ). We thus wanted to address whether RBPJ primarily controls Th17 cell differentiation through regulating IL-17A expression or through regulating IL-23R expression.
To this end, we retrovirally overexpressed IL-23R in IL17A and 5B), although the effect was small. To further dissect whether RBPJ mainly controls expression of IL-17 or IL-23R, we generated IL-23R/RBPJ double-deficient mice by crossing IL17A
Cre RBPJ fl/fl mice with IL23R GFP/GFP mice that lack functional IL-23R at homozygosity (Awasthi et al., 2009 Figures 5C and 5D ). This was in contrast to the reduced differentiation of pathogenic Th17 cells we had observed in IL17A To address the importance of RBPJ in driving IL-23R expression versus IL-17 expression in vivo, we retrovirally overexpressed IL-23R in pathogenic 2D2 (expressing a MOG 35-55 -specific TCR) Th17 cells before transferring them into wild-type hosts. We found that overexpression of IL-23R partially rescued the protection from EAE conferred by RBPJ deficiency (Figure 5E) . Conversely, knockout of IL-10 in 2D2 Th17 cells using a clustered regularly interspaced short palindromic repeats/ CRISPR associated protein 9 (CRISPR/Cas9) lentiviral system did not rescue the protection from EAE conferred by RBPJ deficiency ( Figure 5F ), and neutralization of IL-10 did not revert protection from actively induced EAE in CD4 Cre RBPJ fl/fl mice ( Figure S5D ). Together, these data indicate that driving IL-23R expression, not driving IL-17 or repressing IL-10, is the dominant function of RBPJ in Th17 cells in vivo.
Of note, RBPJ-deficient IL17A Cre RBPJ fl/fl IL23R GFP/GFP pathogenic (IL-1b + IL-6 + IL-23) Th17 cells also produced higher amounts of IL-10 detected by ELISA, although not by intracellular cytokine staining, than RBPJ-competent IL17A
Cre RBPJ fl/wt IL23R GFP/GFP Th17 cells ( Figure 5D ). Thus, RBPJ deficiency enhances production of the non-pathogenic cytokine IL-10 even in the absence of IL-23R. This indicated that RBPJ may also serve as a repressor of IL-10 production in Th17 cells in vitro independently from its effect on IL-23R expression and although this is not its dominant function in vivo ( Figures 5E  and 5F ).
RBPJ Serves as a Repressor of c-Maf-induced IL-10 Production in Th17 Cells
The transcription factor c-Maf is a known inducer of IL-10 in type 1 regulatory (Tr1) cells induced by IL-27 (Apetoh et al., 2010) and in Th17 cells (Bauquet et al., 2009; Xu et al., 2009 ), and we thus speculated that RBPJ may act as a repressor of the regulatory module, including IL-10 controlled by c-Maf in Th17 cells. We overexpressed c-Maf in Th17 cells generated in the presence of TGF-b1 + IL-6 and found that, in CD4 Cre RBPJ fl/fl cells, c-Maf overexpression induced more IL-10 than in wild-type cells (Figures 6A and 6B) . We conclude that RBPJ may serve as a transcriptional repressor of c-Maf-induced IL-10 expression in Th17 cells. The IL-10 genomic locus contains multiple predicted RBPJ binding sites, and ChIP-PCR confirmed binding of RBPJ to the IL-10 locus in Th17 cells ( Figure 6C ). Of note, two previously identified c-Maf response elements (MAREs) in the Il10 promoter (Apetoh et al., 2010) were located within a 150-bp range of predicted RBPJ binding sites ( Figure 6C ). We did not observe protein-protein interaction between RBPJ and c-Maf ( Figure S6 ). Using a luciferase assay, we observed that nonmodified RBPJ inhibited c-Maf-induced activation of the IL-10 promoter ( Figure 6D ), indicating that RBPJ can indeed repress IL-10 production induced by c-Maf. In conclusion, we identify RBPJ as an essential transcriptional regulator controlling the generation of pathogenic and non-pathogenic Th17 cells by promoting the expression of IL-23R and repressing the production of IL-10. However, the effects of RBPJ on IL-23R are dominant in promoting the pathogenic phenotype of Th17 cells in vivo.
DISCUSSION
Our previously generated transcriptional network of Th17 cells implicated RBPJ, the canonical Notch signaling molecule, as a positive regulator of Th17 differentiation (Yosef et al., 2013) . Although the previous study had relied on analysis and perturbation on the mRNA level, here we examined RBPJ in Th17 cells with technically more stringent approaches by testing for the in vitro differentiation and the in vivo function of Th17 cells in the absence of RBPJ and identifying the mechanisms by which RBPJ controls Th17 cell differentiation. Using different genetic approaches, we observed that RBPJ deficiency does not affect the early stage of Th17 cell differentiation but, rather, affects the stabilization stage when Th17 cells are rendered pathogenic through the effects of IL-23. We further demonstrate that RBPJ is required to maintain a pathogenic state of Th17 cells by driving expression of IL-23R and by repressing production of the anti-inflammatory cytokine IL-10. RBPJ thus serves a highly specific purpose in Th17 cells: to promote the pathogenicity of Th17 cells by promoting the expression of members of the pro-inflammatory module and repressing expression of the regulatory module. Therefore, this observation expands the array of functions of the Notch signaling pathway in the differentiation of various T cell subsets (reviewed in Amsen et al. (2009) . Consistent with our observations, pharmacological inhibition of Notch cleavage or Notch ligand binding was previously shown to ameliorate EAE (Bassil et al., 2011; Jurynczyk et al., 2008; Keerthivasan et al., 2011; Maekawa et al., 2015; Reynolds et al., 2011) , but the mechanisms were not elucidated. Here we did not rely on pharmacological inhibitors but, rather, used genetic approaches to ablate the canonical Notch signaling molecule RBPJ in a cell-type-specific manner in Th17 cells. Driving Cre expression from the endogenous Il17a promoter or from an Il17f bacterial artificial chromosome/clone (BAC) transgenic line (Croxford et al., 2009; Hirota et al., 2011) (Tanigaki and Honjo, 2007) , the differentiation of several T helper cell lineages (Amsen et al., 2009; Bailis et al., 2013) , the longevity of helper cells in vitro (Helbig et al., 2012) , the expression of chemokine receptors in vitro (Reynolds et al., 2011) , and the survival of memory T cells in a re-stimulation paradigm in vivo (Maekawa et al., 2015) . However, by using Th17 cell-specific deletion of RBPJ, we did not find evidence for survival-related effects in our experimental setting ( Figures S5A-S5E) , and, by overexpressing IL-23R (Figure 5 ), we demonstrate that RBPJ regulates Th17 pathogenicity specifically by controlling IL-23R expression. By generating RBPJ/IL-23R double-deficient mice and by overexpressing IL-23R in Th17 cells transferred in vivo, we also demonstrate that the dominant function of RBPJ in Th17 cells in vivo is to promote the expression of IL-23R and the pathogenic functional state of Th17 cells.
Th17 cells do not all induce autoimmune disease. It is becoming increasingly clear that Th17 cells mediate tissue homeostasis at mucosal surfaces. In fact, IL-17 production by T cells may serve a protective function in the gut without inducing tissue inflammation (O'Connor et al., 2009) , and gutresident Th17 cells partly resemble non-pathogenic Th17 cells that co-produce IL-17 and IL-10 ( Esplugues et al., 2011; Gagliani et al., 2015) . These different functional states of Th17 cells may have evolutionarily arisen to defend against specific pathogens, as shown in humans (Zielinski et al., 2012) . Identifying the factors controlling the balance between such pathogenic and non-pathogenic Th17 cells may provide the key to understanding how to inhibit pathogenic Th17 cells that induce tissue inflammation and autoimmune diseases but spare those that maintain gut barrier functions and promote tissue homeostasis. Our data indicate that the Notch signaling pathway may be one of the key checkpoints in determining the balance between the pathogenic and non-pathogenic states of Th17 cells. The biological importance is further strengthened by genetic linkage of the RBPJ genomic locus with rheumatoid arthritis (Stahl et al., 2010) , in which Th17 cells are important (Miossec and Kolls, 2012) .
In the canonical Notch signaling pathway, RBPJ is bound to DNA and acts as a transcriptional repressor in the absence of NICD (Amsen et al., 2009) . Only after ligand binding will NICD trans-locate to the nucleus and convert RBPJ to a transcriptional co-activator (Amsen et al., 2009) . RBPJ can thus exert dual functions as either a transcriptional repressor or inducer depending on the nuclear availability of NICD and, thus, on the activity of the Notch pathway. This dual function of RBPJ may account for the induction of IL-10 by NICD in Th1 cells (Kassner et al., 2010; Rutz et al., 2008) but inhibition of IL-10 by RBPJ, which we describe here. In fact, overexpression of NICD also induces IL-10 in Th17 cells (data not shown) in accordance with the dual role of RBPJ as transcriptional activator or repressor. We describe here that the Il10 and Il23r loci respond differently to RBPJ-mediated repression in the absence of Notch pathway activation. RBPJ does not alter cMaf-induced transcription of the Il23r locus but inhibits cMaf-induced transcription of the Il10 locus ( Figure 6 ). The activity of the Notch signaling pathway may thus serve as a transcriptional switch to determine how c-Maf and potentially other transcription factors control the transcription of IL-10 and IL-23R expression in Th17 cells.
We describe here a dual function of RBPJ in Th17 cells as both promoting pathogenicity by inducing IL-23R expression and inhibiting the production of anti-inflammatory IL-10. We therefore identify RBPJ as a transcriptional switch in Th17 cells and provide a mechanistic explanation of how RBPJ can promote the generation of pathogenic Th17 cells and inhibit the generation of non-pathogenic Th17 cells. Our identification of RBPJ as a regulator that can differentially affect pathogenic and non-pathogenic Th17 cells will offer targets to inhibit pathogenic Th17 cells but spare beneficial tissue-protective Th17 cells. (Tanigaki et al., 2002) , IL23R GFP (Awasthi et al., 2009) , and 2D2 (Bettelli et al., 2003) mice were described previously. All experiments were carried out in accordance with guidelines prescribed by the Institutional Animal Care and Use Committee (IACUC) at Harvard Medical School. Ageand sex-matched mice (7-9 weeks old) were immunized for EAE as described previously (Xiao et al., 2014) . IL-10 neutralization in vivo was performed with 500 mg of low endotoxin azide-free rat immunoglobulin G 1 (IgG 1 ) or anti-IL-10 antibody (clone JES5-16E3, BioLegend) intraperitoneally on days 0, 2, and 7 as described previously (McGeachy et al., 2007) . Adoptive transfer of EAE using Th17 differentiated 2D2 cells was performed as described previously ). For transduction before adoptive transfer, 2D2 cells were spin-infected (600 3 g for 45 min at 25 C) with retroviral supernatants on day 1 after plating with Polybrene (8 mg/ml) or with lentiviral supernatants. Cells were not sorted or selected for transduction before transfer.
CD4 + T Cell Differentiation and Retroviral Transduction
high CD25 À naive CD4+ T cells were purified by flow cytometry following magnetic activated cell sorting (MACS) bead isolation of CD4 + cells. Naive T cells were activated with plate-bound anti-CD3 (2 mg/ml, 145-2C11) and anti-CD28 (2 mg/ml, PV-1) antibody in 96-well or 24-well plates. In vitro T cell differentiation was performed for 96 hr. For non-pathogenic Th17 cell differentiation, cultures were supplemented with IL-6 (20 ng/ml) and TGF-b1 (2 ng/ml). For pathogenic Th17 cell differentiation, cultures were supplemented with IL-1b (20 ng/ml), IL-6 (20 ng/ml), and IL-23 (10 ng/ml). Retrovirus-containing supernatants were produced by transiently transfecting HEK293T producer cells with retroviral packaging constructs (PCL-Eco, gag/pol) together with retroviral expression plasmids using Fugene HD (Roche). Culture supernatants were harvested after 72 hr, supplemented with Polybrene (8 mg/ml), and added to sorted naive T cells previously stimulated for 24 hr (1 3 10 5 cells/well, 96-well plate, plate-bound anti-CD3/CD28, both 2 mg/ml, and indicated cytokines). Cultures were centrifuged at 600 3 g for 45 min at 25 C. After an additional 72 hr of culturing, intracellular cytokine staining was performed. Gating was on CD4 + 7AAD À Thy1.1 + cells. The CRISPR/Cas9 was described previously (Parnas et al., 2015) . Cas9 was driven by a modified embryonal fyn-associated substrate (EF-S) promoter, and single guide RNA (sgRNA) was driven by a mammalian U6 promoter. Packaging was with a vesicular stomatitis virus G protein (VSV-G) envelope.
Generation of Constructs and Luciferase Assays
The pTA-IL23R plasmid was described previously (Sato et al., 2011) . The pTA-IL23R Dp2 plasmid was generated by PCR site-directed mutagenesis modifying the GTGGGAA sequence at À1,151 bp from the Il23r transcriptional start site (TSS) to GTAAAAA. The pGL4-IL23R construct was generated by PCR, amplifying a 2. 
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